Kathryn Vanderlaag

Kathryn Vanderlaag has a diverse work experience spanning various roles and companies. Kathryn is currently the Chief Scientific Officer at Eigen Therapeutics since August 2022. Prior to this, they worked at Notable as the Vice President of Research and Development from January 2020 to June 2022. Before that, they held multiple positions at Bristol-Myers Squibb, including Principal Scientist in Immuno-Oncology, Senior Scientist in Immuno-Oncology, and Scientist, between 2014 and 2020. Kathryn also has experience from their time at Novartis Institutes for BioMedical Research as a Research Investigator, where they managed and developed a research group focused on target identification and validation for oncology. Kathryn started their career as a Postdoctoral Fellow at Schering-Plough Research Institute and as a Research Assistant at Health Canada.

Kathryn Vanderlaag has a Bachelor of Science degree from the University of Guelph. Kathryn also holds a PhD from Texas A&M University. No specific start or end years were provided for both their education experiences.